TrivarX Limited

TRI

AU0000300196

Pharmaceuticals

End-of-day quote Australian S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
0.027 ^AUD	-3.57%		-10.00%	-10.00%

05-02	TrivarX Receives Firm Commitments for AU$2.5 Million Share Issuance; Shares Jump 27%	MT
02-28	TrivarX Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

February 16, 2022 at 10:20 pm

Medibio Limited welcomed Stephen Mitchley on Medibio's Board of Directors as Non-Executive Director with immediate effect. Stephen is based in New York and leads Vitality Group's digital and global partner disciplines. He brings 25 years of experience and expertise in overseeing operations and technology to the Vitality Group product team.

Latest news about TrivarX Limited

TrivarX Receives Firm Commitments for AU$2.5 Million Share Issuance; Shares Jump 27%	05-02	MT
TrivarX Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
TrivarX Signs Collaboration with Northern Michigan University on Sleep Research	02-09	MT
TrivarX Secures R&D Tax Rebate for Fiscal Year 2023; Shares Fall 4%	02-08	MT
Over Half of Patients On Track for Completion in TrivarX's SAMDE Study	02-07	MT
TrivarX Undertaking 1-for-20 Securities Consolidation	18/10/23	MT
Medibio Limited has Changed its Name to TrivarX Limited	06/10/23	CI
Medibio Limited Announces Dr. Thomas Young Will Transition from His Role as Part-Time Chief Executive Officer to Non-Executive Director	06/10/23	CI
Medibio Limited Announces Dr. Thomas Young Will Transition from His Role as Part-Time Chief Executive Officer to Non-Executive Director	06/10/23	CI
Medibio Begins Phase Two Trial for Sleep Algorithm	04/09/23	MT
TrivarX Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Medibio Completes Phase One Depressive Episode Sleep Trial	24/07/23	MT
US FDA Denies Breakthrough Device Designation for Medibio’s Depression Diagnostic Device	21/07/23	MT
Medibio Completes Shares Purchase Plan	29/05/23	MT
Medibio Adds Executive Director Role to CEO, Changes Principal Pace of Business	12/04/23	MT
Medibio Limited Announces Board & Management Changes	12/04/23	CI
Medibio Limited Announces Change of Registered Office and Principal Place of Business	12/04/23	CI
Medibio Limited Announces Resignation of Matt Mesnik as Non-Executive Director	16/03/23	CI
Medibio Limited Lodges Breakthrough Device Designation with FDA	26/02/23	CI
TrivarX Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/02/23	CI
Medibio Limited Appoints Christopher Ntoumenopoulos as Director	16/02/23	CI
Medibio to Raise AU$2.8 Million in Placement, Share Purchase Plan	15/02/23	MT
Medibio Receives R&D Tax Rebate	15/11/22	MT
Medibio Limited Announces Resignation of Stephen Mitchley as a Director	10/11/22	CI
Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair	26/10/22	CI

Chart TrivarX Limited

Duration

Period

More charts

Company Profile

TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Companyâs corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is conducting clinical research, product development and early-stage commercialization of a mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. It has launched its consumer mobile application to help measure, monitor, and manage stress, called LUCA. LUCA is a biometric assessment tool that measures sleep stress, activity stress, and cardiac stress that allows consumers to monitor their daily stress levels through their own personal wearable device.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
TRIVARX LIMITED	-10.00%	6.31M
MERCK KGAA	+16.34%	79.03B
KYOWA KIRIN CO. LTD.	+8.65%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	4.83B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.22%	4.65B
YUHAN CORPORATION	+2.18%	3.89B
INDIVIOR PLC	+20.51%	2.34B
BETTA PHARMACEUTICALS CO., LTD.	-26.79%	2.18B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.12%	2.11B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.56%	2B

Specialty & Advanced Pharmaceuticals

TrivarX Limited

Equities

TRI

AU0000300196

Pharmaceuticals

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Latest news about TrivarX Limited

Chart TrivarX Limited

Company Profile

Income Statement Evolution

Chiffre d''affaires - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals